Evolution of Biocatalysis at Novartis over the last 40 Years

Elina Siirola; Fabian Eggimann; Charles Moore; Kirsten Schroer; Alexandra Vargas; Theo Peschke; Thierry Schlama; Radka Snajdrova

doi:10.2533/chimia.2023.376

Evolution of Biocatalysis at Novartis over the last 40 Years

Authors

Elina Siirola Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
Fabian Eggimann Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
Charles Moore Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
Kirsten Schroer Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
Alexandra Vargas Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
Theo Peschke Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
Thierry Schlama Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
Radka Snajdrova Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108

DOI:

https://doi.org/10.2533/chimia.2023.376

PMID:

38047776

Keywords:

Biocatalysis, Bioinformatics, Enzyme evolution, Late-stage functionalization, Metabolite synthesis

Abstract

The fortieth anniversary of biocatalysis started at Ciba-Geigy and later at Novartis is a great time to pause and reflect on development of science and technology in this field. Enzyme-based synthesis became a highly valued enabling tool for pharmaceutical research and development over the last decades. In this perspective we aim to discuss how the scientific approaches and trends evolved over the time and present future challenges and opportunities.

CHIMIA Vol. 77 No. 6 (2023): Biocatalysis

Downloads

Published

2023-06-28

How to Cite

[1]

E. Siirola, F. Eggimann, C. Moore, K. Schroer, A. Vargas, T. Peschke, T. Schlama, R. Snajdrova, Chimia 2023, 77, 376, DOI: 10.2533/chimia.2023.376.